Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response.
cytotoxicity, immunologic
gene expression profiling
genetic markers
genome Instability
immunotherapy
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
accepted:
24
01
2020
entrez:
8
5
2020
pubmed:
8
5
2020
medline:
21
8
2021
Statut:
ppublish
Résumé
An immune active cancer phenotype typified by a T helper 1 (Th-1) immune response has been associated with increased responsiveness to immunotherapy and favorable prognosis in some but not all cancer types. The reason of this differential prognostic connotation remains unknown. To explore the contextual prognostic value of cancer immune phenotypes, we applied a multimodal pan-cancer analysis among 31 different histologies (9282 patients), encompassing immune and oncogenic transcriptomic analysis, mutational and neoantigen load and copy number variations. We demonstrated that the favorable prognostic connotation conferred by the presence of a Th-1 immune response was abolished in tumors displaying specific tumor-cell intrinsic attributes such as high transforming growth factor-beta (TGF-β) signaling and low proliferation capacity. This observation was independent of mutation rate. We validated this observation in the context of immune checkpoint inhibition. WNT- This is the first systematic study demonstrating that the prognostic and predictive role of a bona fide favorable intratumoral immune response is dependent on the disposition of specific oncogenic pathways. This information could be used to refine stratification algorithms and prioritize hierarchically relevant targets for combination therapies.
Sections du résumé
BACKGROUND
An immune active cancer phenotype typified by a T helper 1 (Th-1) immune response has been associated with increased responsiveness to immunotherapy and favorable prognosis in some but not all cancer types. The reason of this differential prognostic connotation remains unknown.
METHODS
To explore the contextual prognostic value of cancer immune phenotypes, we applied a multimodal pan-cancer analysis among 31 different histologies (9282 patients), encompassing immune and oncogenic transcriptomic analysis, mutational and neoantigen load and copy number variations.
RESULTS
We demonstrated that the favorable prognostic connotation conferred by the presence of a Th-1 immune response was abolished in tumors displaying specific tumor-cell intrinsic attributes such as high transforming growth factor-beta (TGF-β) signaling and low proliferation capacity. This observation was independent of mutation rate. We validated this observation in the context of immune checkpoint inhibition. WNT-
CONCLUSIONS
This is the first systematic study demonstrating that the prognostic and predictive role of a bona fide favorable intratumoral immune response is dependent on the disposition of specific oncogenic pathways. This information could be used to refine stratification algorithms and prioritize hierarchically relevant targets for combination therapies.
Identifiants
pubmed: 32376723
pii: jitc-2020-000617
doi: 10.1136/jitc-2020-000617
pmc: PMC7223637
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: TT, KH, and JS are employees of AbbVie Biotherapeutics. MC was an employee of AbbVie Biotherapeutics at the time the research was conducted and has currently a consulting relationship with AbbVie. FMM is an employee of Refuge Biotechnologies. EW is an employee of Allogene Therapeutics
Références
Clin Cancer Res. 2019 May 15;25(10):3074-3083
pubmed: 30635339
Oncoimmunology. 2016 Oct 18;5(12):e1240857
pubmed: 28123876
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
Cancer Immunol Res. 2016 Jul;4(7):600-10
pubmed: 27197066
Biochem Soc Trans. 2013 Apr;41(2):687-93
pubmed: 23514177
J Immunother Cancer. 2018 Jun 22;6(1):63
pubmed: 29929551
Cell Syst. 2018 Mar 28;6(3):271-281.e7
pubmed: 29596782
BMC Bioinformatics. 2011 Dec 17;12:480
pubmed: 22177264
Cancer Discov. 2017 Dec;7(12):1420-1435
pubmed: 29025772
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Cell. 2018 Nov 1;175(4):998-1013.e20
pubmed: 30388456
Cancer Res. 2016 Mar 1;76(5):999-1008
pubmed: 26833127
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
Nat Commun. 2017 Oct 26;8(1):1136
pubmed: 29070816
Genome Biol. 2011;12(4):R41
pubmed: 21527027
Oncoimmunology. 2017 Feb 6;6(2):e1253654
pubmed: 28344865
Nat Biotechnol. 2012 May;30(5):413-21
pubmed: 22544022
Cancer Cell. 2018 Apr 9;33(4):676-689.e3
pubmed: 29622463
Nat Commun. 2017 Oct 19;8(1):1050
pubmed: 29051489
Oncotarget. 2017 Oct 31;8(62):106132-106142
pubmed: 29285320
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7759-E7768
pubmed: 27837020
J Immunol. 2010 Jun 1;184(11):6133-41
pubmed: 20483781
J Clin Oncol. 2013 Jul 1;31(19):2369-71
pubmed: 23715576
Exp Ther Med. 2018 Jul;16(1):133-140
pubmed: 29896233
BMC Cancer. 2016 Nov 22;16(1):911
pubmed: 27871313
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Cancer Res. 2017 Mar 15;77(6):1271-1282
pubmed: 28126714
J Immunother Cancer. 2018 Jan 23;6(1):8
pubmed: 29357948
Clin Cancer Res. 2015 Jul 1;21(13):3031-40
pubmed: 25688160
Cancer Sci. 2019 Aug;110(8):2348-2356
pubmed: 31222843
J Immunother Cancer. 2018 Jun 5;6(1):50
pubmed: 29871670
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Ther Adv Med Oncol. 2017 May;9(5):347-368
pubmed: 28529551
Ann Transl Med. 2016 May;4(9):173
pubmed: 27275486
Science. 2017 Jan 20;355(6322):
pubmed: 28104840
Nat Biotechnol. 2015 Nov;33(11):1152-8
pubmed: 26372948
Br J Cancer. 2005 May 23;92(10):1948-52
pubmed: 15841077
Curr Opin Immunol. 2016 Apr;39:150-8
pubmed: 26967649
Sci Rep. 2019 Jun 12;9(1):8572
pubmed: 31189943
Br J Cancer. 2013 Oct 29;109(9):2412-23
pubmed: 24129241
Eur J Cancer. 2017 Aug;81:116-129
pubmed: 28623775
Oncoimmunology. 2018 Dec 12;8(3):1548241
pubmed: 30723576
Cancer Discov. 2016 Aug;6(8):827-37
pubmed: 27301722
Cell. 2018 Oct 18;175(3):751-765.e16
pubmed: 30318143
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Nat Rev Genet. 2019 Jun;20(6):317
pubmed: 30980030
Lung Cancer (Auckl). 2018 May 18;9:45-47
pubmed: 29844707
J Transl Med. 2011 Oct 12;9:174
pubmed: 21992116
Int J Mol Sci. 2017 Oct 24;18(10):
pubmed: 29064420
Nature. 2009 Nov 5;462(7269):108-12
pubmed: 19847166
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
Curr Opin Oncol. 2015 Nov;27(6):433-44
pubmed: 26418235
J Clin Invest. 2014 May;124(5):2147-59
pubmed: 24691438
Cell Rep. 2017 Jan 3;18(1):248-262
pubmed: 28052254
Immunity. 2013 Jul 25;39(1):11-26
pubmed: 23890060
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Pathol Res Pract. 2019 Jan;215(1):209-214
pubmed: 30503610
Int J Cancer. 2014 Jan 1;134(1):102-13
pubmed: 23784959
Ann N Y Acad Sci. 2013 May;1284:75-9
pubmed: 23651198
J Immunother Cancer. 2019 May 22;7(1):131
pubmed: 31113486
Immunity. 2017 Feb 21;46(2):197-204
pubmed: 28228279
PLoS One. 2017 Jul 27;12(7):e0179726
pubmed: 28749946
Oncoimmunology. 2018 Jul 30;7(10):e1490854
pubmed: 30386679
Nat Rev Cancer. 2018 Mar;18(3):139-147
pubmed: 29326431
Oncoimmunology. 2015 Aug 31;5(3):e1086862
pubmed: 27141343
Cell. 2018 Apr 5;173(2):291-304.e6
pubmed: 29625048
Cancer Discov. 2016 Feb;6(2):202-16
pubmed: 26645196
Cancer Immunol Res. 2016 Jul;4(7):563-8
pubmed: 27197067
N Engl J Med. 2006 Jun 29;354(26):2751-63
pubmed: 16807412
Genome Biol. 2013 Apr 29;14(4):R34
pubmed: 23618380
Br J Cancer. 2018 Nov;119(11):1383-1391
pubmed: 30353048
Nat Commun. 2018 Nov 8;9(1):4692
pubmed: 30410077
Immunity. 2018 Jan 16;48(1):147-160.e7
pubmed: 29343435
Breast Cancer Res Treat. 2019 Sep;177(2):335-343
pubmed: 31222709
Nat Commun. 2017 Jun 06;8:15180
pubmed: 28585546
F1000 Med Rep. 2012;4:8
pubmed: 22500192
Cancer Res. 2017 Jul 1;77(13):3540-3550
pubmed: 28487385
Front Immunol. 2018 Jul 16;9:1649
pubmed: 30061899
Nat Med. 2019 Mar;25(3):462-469
pubmed: 30742119
Clin Cancer Res. 2018 Aug 1;24(15):3717-3728
pubmed: 29666300
Cell Res. 2017 Jan;27(1):96-108
pubmed: 27981969
Cell. 2016 Jul 28;166(3):740-754
pubmed: 27397505
Trends Immunol. 2008 Jun;29(6):256-62
pubmed: 18457994